Cargando…

Editorial: Response assessment of radioligand therapies

Detalles Bibliográficos
Autores principales:	Lopci, Egesta, Prasad, Vikas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364693/ https://www.ncbi.nlm.nih.gov/pubmed/35965585 http://dx.doi.org/10.3389/fonc.2022.904337

Ejemplares similares

Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1
por: Castello, Angelo, et al.
Publicado: (2020)

Additional value of volumetric and texture analysis on FDG PET assessment in paediatric Hodgkin lymphoma: an Italian multicentric study protocol
por: Lopci, Egesta, et al.
Publicado: (2021)

Advances in Lung Cancer Imaging and Therapy
por: Lopci, Egesta, et al.
Publicado: (2021)

18F-FDG PET/CT in Restaging and Evaluation of Response to Therapy in Lung Cancer: State of the Art
por: Castello, Angelo, et al.
Publicado: (2020)

Meditating on Cancer Management at the Time of Immunotherapy
por: Lopci, Egesta
Publicado: (2022)

Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [(18)F]FDG PET/CT in Metastatic Melanomas and Lung Cancer
por: Lopci, Egesta
Publicado: (2021)

Case Report: Long-term complete response to PSMA-targeted radioligand therapy and abiraterone in a metastatic prostate cancer patient
por: Parker, David, et al.
Publicado: (2023)

Theranostic (64)Cu-DOTHA(2)-PSMA allows low toxicity radioligand therapy in mice prostate cancer model
por: Milot, Marie-Christine, et al.
Publicado: (2023)

Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors
por: Castello, Angelo, et al.
Publicado: (2021)

Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer
por: Puranik, Ameya D, et al.
Publicado: (2021)

Metabolic Imaging in B-Cell Lymphomas during CAR-T Cell Therapy
por: Linguanti, Flavia, et al.
Publicado: (2022)

(177)Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians
por: Bu, Ting, et al.
Publicado: (2022)

FDG PET/CT for assessing tumour response to immunotherapy: Report on the EANM symposium on immune modulation and recent review of the literature
por: Aide, Nicolas, et al.
Publicado: (2018)

Editorial: Imaging assessment of response to immunotherapy
por: Occhipinti, Mariaelena, et al.
Publicado: (2023)

Treatment of Advanced Metastatic Prostate Cancer Using Molecular-Targeted Therapy: Radioligand Lutetium-177 Prostate-Specific Membrane Antigen
por: Rathore, Rajni, et al.
Publicado: (2023)

1606P Developing a readiness assessment framework for radioligand therapy
por: Plucker, E., et al.
Publicado: (2020)

The Role of Radiomics in the Era of Immune Checkpoint Inhibitors: A New Protagonist in the Jungle of Response Criteria
por: Castello, Angelo, et al.
Publicado: (2022)

Pharmacological Optimization of PSMA-Based Radioligand Therapy
por: van der Gaag, Suzanne, et al.
Publicado: (2022)

Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography
por: Oprea-Lager, Daniela E., et al.
Publicado: (2021)

Editorial: Cancer Plasticity and the Microenvironment: Implications for Immunity and Therapy Response
por: Behren, Andreas, et al.
Publicado: (2019)

Radioligand therapies in cancer: mapping the educational landscape in Europe
por: Bugani, Valentina, et al.
Publicado: (2023)

Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters
por: Castello, Angelo, et al.
Publicado: (2020)

Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group – ESOI Joint Paper
por: Fournier, Laure, et al.
Publicado: (2022)

Metal-Based PSMA Radioligands
por: Gourni, Eleni, et al.
Publicado: (2017)

Editorial: Neoadjuvant Therapy in Rectal Cancer: Response Prediction and Organ Preservation Strategies
por: Aguiar, Samuel, et al.
Publicado: (2022)

Application of Cleavable Linkers to Improve Therapeutic Index of Radioligand Therapies
por: Lau, Joseph, et al.
Publicado: (2022)

Editorial: Extracellular vesicles as modulators of cancer cell adaptive responses linked to therapy resistance
por: Giordano, Antonio, et al.
Publicado: (2022)

Editorial: Positron Emission Tomography (PET) Imaging of Brain Biochemistry: Beyond High-Affinity Radioligands
por: Kilbourn, Michael R., et al.
Publicado: (2022)

Editorial: PTCL from genes to therapy
por: Janikova, Andrea
Publicado: (2022)

Editorial: Nanomaterials and multimodal tumor therapy
por: Yang, Yongqi, et al.
Publicado: (2022)

Editorial: Therapies and influences in urothelial carcinoma
por: Ozgun, G., et al.
Publicado: (2022)

Editorial: Emerging Therapies for Malignant Mesothelioma
por: van Zandwijk, Nico, et al.
Publicado: (2020)

Editorial: Nanomedicine in Cancer Targeting and Therapy
por: Longo, João Paulo Figueiró, et al.
Publicado: (2021)

Editorial: Image-guided particle therapy
por: Li, Heng, et al.
Publicado: (2023)

Editorial: Microenvironment and therapy-resistance in leukemias
por: Friedmann, Rachel, et al.
Publicado: (2023)

Editorial: Lymph node assessment in cervical cancer
por: Guani, Benedetta, et al.
Publicado: (2023)

Editorial: Radiomics in prostate cancer imaging
por: Brunese, Luca, et al.
Publicado: (2022)

Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms
por: Iravani, Amir, et al.
Publicado: (2022)

Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
por: Awang, Zool Hilmi, et al.
Publicado: (2018)

Monitoring and Surveillance of Patients with Gastroenteropancreatic Neuroendocrine Tumors Undergoing Radioligand Therapy
por: Halfdanarson, Thorvardur R., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3kh58lfn4fuo572shsdunla0fc